{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The number of participants who had any dose interruptions were planned to be analyzed. However, this analysis was not performed for Part 2 as the study was terminated early during Part 1.","groups":[{"description":"Participants with GCB-DLBCL-mutant and wild type, TFL-mutant and wild type as well as participants with MM were planned to be enrolled in Part 2 of the study. Participants enrolled in Part 2 were planned to receive RP2D .","id":"OG000","title":"Part 2: All Participants"}],"populationDescription":"All Subjects Population. Data was not collected in Part 2 as no participant was enrolled in Part 2.","reportingStatus":"POSTED","timeFrame":"Up to 3.2 years","title":"Part 2: Number of Participants With Dose Interruptions","type":"SECONDARY"}